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Abstract
Background: Schistosomiasis is a major parasitic disease affecting over 200 million people in the
developing world with a further 400 million people at risk of infection. The aim of this study was
to identify a single antigen from adult Schistosoma haematobium worms and subsequently use this
antigen to study the development of schistosome-acquired immunity in a human population.
Methods: The full-length cDNA sequence of a S. haematobium protein, a putative orthologue of
the S. mansoni tegumental antigen Sm13, was obtained from a cDNA library of adult S. haematobium
worms and named Sh13 following a small-scale expressed sequence tags (EST) project. The
recombinant Sh13 protein expressed in E. coli, was used to investigate immuno-epidemiological
patterns in 147 Zimbabweans (7–18 years old) exposed to S. haematobium.
Results: Sequence analysis of the full-length cDNA sequence of the S. haematobium protein Sh13,
indicated that the protein has an N-terminal signal peptide and encodes an 85-amino acid mature
protein with a highly conserved predicted transmembrane domain (86 % identity with the S.
mansoni tegumental antigen Sm13). The recombinant Sh13 protein was used in ELISA assays to
determine the reactivity of sera from the study participants. Antibody responses against Sh13 were
predominantly IgG3 isotype compared to responses against crude worm antigens which were
predominantly IgG1 and IgG4. The relationship between anti-Sh13 IgG3 levels and infection
intensity varied significantly with host age. The youngest children (7–10 years old) had relatively
low levels of both infection and anti-Sh13 IgG3. In older children (11–12 years old) rising infection
levels were accompanied by a significant increase in anti-Sh13 IgG3 levels. Subsequently, infection
intensity declined significantly in 13–18 year olds but levels of the antibody continued to rise. The
changing relationship between infection intensity and anti-Sh13 IgG3 levels with host age is
consistent with the profile of a protective immune response predicted from theoretical work.
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Conclusion: We have identified and characterised a novel S. haematobium antigen Sh13, a putative
tegumental protein, and shown that it is recognised predominantly by IgG3 antibodies from people
infected with/exposed to S. haematobium parasites. We have also shown that, the anti-Sh13 IgG3
response is maximal in older individuals with the lowest infection intensity, and that the age profile
of the relationship between anti-Sh13 IgG3 and infection intensity is consistent with that predicted
by theoretical work for a protective response stimulated by and directed against adult worms.
Background
Schistosomiasis is a major parasitic disease in developing
countries in Africa, the Middle East, Latin America and
Asia where it is estimated that 200 million people are
infected with the parasite while a further 600 million are
at risk of infection [1]. Schistosoma haematobium, the caus-
ative agent of urinary schistosomiasis occurs in 53 coun-
tries across Africa and the Middle East where it is
responsible for the majority of schistosome-associated
pathology. A recent survey in sub-Saharan Africa indicates
that 70 million individuals out of 682 million had experi-
enced haematuria with 32 million cases of dysuria associ-
ated with S. haematobium infection [2]. Furthermore, it
was estimated that 18 million people suffer S. haemato-
bium-related bladder wall pathology and 10 million suffer
hydronephrosis [2].
Despite its public health importance, S. haematobium is
the species least studied with respect to immune
responses directed against the parasite and identification
of specific antigens. In particular, few specific antigens
have been identified or used for immuno-epidemiological
research. In the present work, we describe the identifica-
tion of a S. haematobium protein that, based on similarity
to the already known S. mansoni antigen Sm13 [3], was
named Sh13. Sm13 has been immunolocalised to the teg-
ument of adult parasites and found to be recognised by
total IgG from the sera of 7 Brazilians infected with S.
mansoni [3]. The main aim of this study was to determine
the immuno-epidemiological profile of anti-Sh13
responses in a Zimbabwean population exposed to S. hae-
matobium infection. Use of a single antigen allows defini-
tion of response dynamics over time, which may differ
markedly from those directed against other antigens.
In experimental studies, adult S. haematobium worms have
been shown to suffer immune mediated attrition and
reduction of fecundity [4-6] and, as early as 1934, Fisher
postulated that the epidemiology of human schistosome
infections reflects these immunological processes [7].
More recently, Woolhouse used theoretical methods to
predict the profiles which these immune responses would
follow in a host population [8,9] and effectively set the
framework for the immuno-epidemiology of helminth
infections. Since then, several field studies have been con-
ducted in various countries to identify the immune
responses responsible for these effects and to describe the
immuno-epidemiology of the infection in human popu-
lations [10-18]. Identifying which of these responses are
protective has been complicated by several factors, includ-
ing the concurrent presence in the host of different para-
site developmental stages with shared antigens, the short
duration of protective responses and the limited degree of
protection they provide as suggested by theoretical work
[19,20]
Identifying patterns consistent with acquired immunity
from field studies of infected populations has proven very
difficult [21]. This is largely due to the epidemiology of
infection, inherent variability in infection intensity data
and the presence of factors which confound the relation-
ship between infection levels and immune responses
[8,21-23]. One useful approach is to employ results of
quantitative work predicting patterns of immunity in pop-
ulations, which has proved successful in other studies
[14,20]. The quantitative studies predict the patterns
which the immune responses should follow within the
population if they are protective [8,24]. Therefore, in this
study we test the predictions from quantitative work on
schistosome immunity and determine if the responses to
Sh13 in the study population follow these predictions.
Patterns of immunity are more likely to be detected in
groups of the population showing the most pronounced
changes in infection levels [8,24]. In schistosome-infected
populations, children carry the heaviest parasite burdens
and the greatest changes in infection levels occur in the
first two decades of life [7,25]. Therefore, we focus on
antibody responses of children and young adults in
whom the rates of acquisition and elimination of infec-
tion are changing most rapidly. In addition, we take into
account that results from the traditionally used correla-
tion analyses across the whole population are difficult to
interpret, because they arise from a heterogeneous group
of people where infection dynamics differ considerably,
particularly the history of infection [14]. For this reason,
our study uses an age-structured analysis of the cross-sec-
tional data which partitions the population into groups of
people with similar histories of infection, enabling com-
parative analyses of the changing relationship between
infection intensity and immune responses to be con-
ducted. Theoretical studies and field studies in the hook-BMC Infectious Diseases 2006, 6:96 http://www.biomedcentral.com/1471-2334/6/96
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worm Necator americanus have shown the age structured
analysis to be powerful in detecting immune responses
associated with protection against infection or re-infec-
tion [8,24,26].
Methods
Study area
The study was conducted in the Mashonaland East Prov-
ince of Zimbabwe (31°30'E; 17°45'S) where S. haemato-
bium is endemic. The study area is described in detail
elsewhere [13]. Permission to conduct the work in this
province was obtained from the Provincial Medical Direc-
tor. The villages were selected because health surveys con-
ducted regularly by the Provincial Medical Director in the
region showed little or no infection with other helminths
and a low S. mansoni prevalence (< 5%). The selected vil-
lages had not been included in the National Schistosome
Control Programme and therefore had not received treat-
ment for schistosomiasis or other helminth infections.
The main activity in these villages is subsistence farming
and human water contact is frequent with at least 4 con-
tacts/person/week due to insufficient safe water and sani-
tation facilities (see [13] for studies in neighbouring
villages). Drinking water is collected from open wells
while bathing and washing is conducted in two main riv-
ers in the villages. Most families maintain a garden located
near the river where water is collected for watering the
crops. The schools surveyed (a secondary school and its
feeder primary school (i.e. where the majority of the pri-
mary school children come from) Goromonzi and
Shangure in Goromonzi, and Chindenga and Nyambanje
in Mutoko) were all in close proximity to rivers.
Study subjects
Only permanent inhabitants of the villages who had never
been treated for any helminth infection were eligible for
inclusion in the study. Following explanation of the
project aims and procedures to the community, school
children and their teachers, an initial parasitology (stool
and urine samples) and serology (blood sample) survey
was conducted amongst all compliant participants. A
questionnaire survey (data not shown) confirmed that on
average, all participants frequented water contact sites at
least four times per week and that frequency of water con-
tacts at these sites was not significantly different within
the age range included in this study. Stool samples were
processed following the Kato-Katz procedure [27] to
detect  S. mansoni eggs and other intestinal helminths,
while the urine filtration method [28] was used to detect
S. haematobium eggs in urine samples. After collection of
the samples, all participants were offered treatment with
the recommended dose of praziquantel, 40 mg/kg body
weight. In order to be included in the cohort, participants
had to meet all the following criteria: 1) have provided at
least 2 urine and 2 stool samples on consecutive days; 2)
have given a blood sample; 3) be negative for intestinal
helminths including S. mansoni (all people meeting crite-
ria 1 and 2 were egg negative for intestinal helminths
including  S. mansoni, therefore, no participants were
excluded on this criterion). 147 people aged between 7
and 18 years met these criteria. Serum samples obtained
from 20 mls of venous blood from each participant were
frozen and stored in duplicate at -20°C in the field and
transferred to a -80°C freezer in the laboratory. One com-
plete set of the samples was subsequently transported fro-
zen from Zimbabwe to the UK, stored at -80°C and
defrosted for the first time for use in this study.
Parasites
In order to avoid any potential problem of polymorphism
in antigens that may arise due to parasite strain differ-
ences, we used S. haematobium worms collected from a
random selection of the most intensely infected partici-
pants. Eggs were hatched and used to infect snails in the
laboratory in Zimbabwe. After 6 weeks, snails were shed
and the cercariae thus obtained used to infect hamsters,
which were sacrificed at 8 weeks post infection. To sample
from a larger genetic pool, we also collected infected
snails from the water contact sites used by the study pop-
ulation and used these to infect hamsters as above. Adult
worms were recovered by perfusion of the hamsters with
normal saline, washed and stored in Trizol reagent (Invit-
rogen) at -20°C until they were used for RNA extraction.
Identification of Sh13
A small-scale expressed sequence tags (EST) project was
conducted to generate sequences to be used in identifying
antigens from a proteomics study of S. haematobium anti-
gens [29]. As a result of this project a clone coding for a
protein homologous to an already known S. mansoni
adult worm antigen [3] was identified. This provided an
excellent opportunity to study immune responses against
the recombinant protein at a population level.
RNA was extracted from the worms stored in Trizol fol-
lowing the manufacturer's instructions and used to pre-
pare a full-length enriched oligo-capped cDNA library in
the pSPORT vector (Invitrogen) as published elsewhere
[30]. The library was plated out and random colonies
picked for EST sequencing using T7 primer and BigDye
terminator sequencing ready reaction (Applied Biosys-
tems) (see [30]). The sequences were used to search for
similarities in the NCBI database. A cDNA with a trans-
lated sequence highly similar to that of the tegumental S.
mansoni protein Sm13 [3] was thus identified and named
Sh13. Because Taq polymerase had been used in the prep-
aration of the cDNA library and in the generation of the
ESTs, the sequence coding for the putative mature protein
was confirmed by sequencing of clones derived from RT-BMC Infectious Diseases 2006, 6:96 http://www.biomedcentral.com/1471-2334/6/96
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PCR products of parasite RNA amplified with Pfu, a DNA
polymerase with proofreading activity.
Cloning and protein expression
Following identification of the putative full-length cDNA
sequence of Sh13, the coding region was PCR amplified
using specific forward and reverse primers. Because the
protein has a predicted signal sequence between amino
acid residues 1–19, the forward primer, which included a
restriction site for EcoRI (underlined), was designed from
residue 20: 5'-CGAGAATTCCAATCGGGACCTAGTC-
CAATAAAT-3'; the reverse primer contained a site for SalI
(underlined) immediately after the stop codon: 5'-
GCGGTCGACTTAAGATTTCTGTAAATGGTAATATAC-3'.
These primers were used to amplify the Sh13 cDNA with
Pfu DNA polymerase from the same parasite RNA used to
prepare the library. The RT-PCR product thus obtained
was A-tailed with Taq polymerase, gel purified, ligated to
pGEM®-T vector (Promega) and the recombinant plasmid
used to transform E. coli JM109 cells. Inserts were then
released from plasmid DNA by EcoRI and SalI digestion,
and sub-cloned into the pMal-c2x expression vector
(NEB) cut with the same enzymes. Clones were verified by
sequencing. The Sh13/pMal-c2x plasmid was used for
protein expression following induction with IPTG accord-
ing to standard protocols [31]. A control for induction
and maltose binding protein (MBP) expression was also
run using pMal-c2x transformants. The resulting MBP-
Sh13 fusion protein was purified on an amylose column
following the supplier's instructions and its identity veri-
fied by mass spectrometry. The presence of Sh13 in the
fusion protein was further verified by digestion of 20 μl of
MBP-Sh13 protein (1 mg/ml) with 1 íl of Factor Xa, which
cleaves the arginine-isoleucine peptide bond linking MBP
to Sh13. The products of this digestion were run on a gel
and Coomassie blue stained.
Antibody assays
Preliminary titrations with varying antigen concentra-
tions, serum and secondary antibody dilutions were con-
ducted to determine optimal conditions to carry out the
enzyme-linked immunosorbent assay (ELISA) using sera
from endemic normal people (i.e. heavily exposed to
infection but negative for schistosome eggs), negative
controls (i.e. British people who had never travelled to
schistosome endemic areas) and a pool of sera from the
whole population. These titration assays allowed determi-
nation of the serum dilution and antigen concentration
yielding the best discrimination between negative and
positive controls. The Elisa protocol was thus developed.
Assays were conducted using MBP-Sh13 and MBP control
as is standard [3]. ELISA plates (Nunc-Immulon, Den-
mark) were coated with 100 μl/well of 1 μg/ml antigen in
60 mM carbonate-bicarbonate buffer (pH 9.6) and incu-
bated overnight at 4°C. Plates were blocked with 200 μl/
well of skimmed milk (5% milk in phosphate buffered
saline (PBS)/0.03% Tween 20) for 1 hr and washed three
times in PBS/Tween 20, which was used for all washes.
100 μl of serum was added to each well at 1:100 dilution;
plates were incubated overnight at 4°C and then washed
three times. 100 μl of isotype-specific monoclonal anti-
body was added at 1:1000 dilution for the detection of IgA
(Dako, Denmark, P0216), IgE (Vector Laboratories, UK
P0720), IgG1, IgG2, IgG3, IgG4 (The Binding Site, UK,
AP006, AP007, AP008 and AP009, respectively) and IgM
(Dako, Denmark, P0215). Plates were incubated over-
night at 4°C, washed six times and 100 μl of ABTS sub-
strate solution (KPL, Canada) was added. The IgE-specific
antibody was biotinylated; so 100 μl/well of streptavadin-
horseradish peroxidase (Amersham, UK) was added at
1:6000 dilution to these plates, which were then incu-
bated for 1 hr at 37°C, washed 6 times and developed.
The reaction was allowed to take place at 37°C for 30 min
for all isotypes, before the absorbance was read at 405 nm.
Three negative controls used in the titration assays were
included on each ELISA plate and all samples were
assayed in duplicate.
For comparative purposes, antibody assays were also con-
ducted with the conventional crude worm antigen (solu-
ble worm antigen preparation, SWAP) prepared following
standard protocols [13]. These assays were conducted fol-
lowing the same protocol as above using 1 μg/ml SWAP to
coat the plates (a random subset of 41 samples run using
20 μg/ml SWAP together with negative and positive con-
trols showed that similar results were obtained using 1 μg/
ml and 20 μg/ml of SWAP) sera diluted at 1:100, and sec-
ondary antibodies diluted at 1:1000 for IgG1 and 1:500
for IgG2, IgG3, IgG4.
Statistical analyses
In order to characterise the study population, preliminary
analysis of variance (ANOVA) tests followed by post hoc
procedures using the software package SPSS, were con-
ducted on mean infection intensity (log10 (x+1) trans-
formed) to determine the age groupings relative to
infection level, i.e. age groups where infection levels are
rising, peaking, and declining. After partitioning the pop-
ulation into the appropriate age groups, further tests were
conducted on mean infection intensity (log10 (x+1) trans-
formed) and antibody level (square root transformed) to
determine if these changed between the age groups. Chi-
squared tests were also conducted on the corresponding
prevalence data for the groups. These tests partitioned the
population into 4 age groups where infection levels are
rising, peaking, declining and lowest.
Statistical analyses to determine factors associated with
the level of antibody responses against Sh13 were con-
ducted by ANOVA, with antibody level (square root trans-BMC Infectious Diseases 2006, 6:96 http://www.biomedcentral.com/1471-2334/6/96
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formed) as the dependent variable, sex (2 categories) and
age (4 categories as above) as the independent variables.
The interaction between age and infection intensity was
also tested. The correlation between infection intensity
(log10 (x+1) transformed) and antibody levels (square
root transformed) was determined using a one-tailed
Pearson correlation and the correlation coefficients thus
obtained used to test for homogeneity between coeffi-
cients from the different age groups by the method of Zar
[32]. The correlation analyses and homogeneity tests were
also performed excluding egg negative people; the results
reported here include all participants because exclusion of
egg negative people did not significantly affect the results.
Results
Sequence analysis of Sh13
In characterising a new cDNA library derived from adult
S. haematobium worms we identified a clone coding for the
putative orthologue of the S. mansoni tegumental protein
Sm13 [3]. This cDNA was thus named Sh13. The full-
length 312-nt ORF encodes a 104-aa protein with a theo-
retical mass and isoelectric point (pI) of 11,651 Da and
6.39 respectively calculated using ExPASy Software [33].
SignalP software [34] analysis predicted a signal peptide
with a cleavage site between amino acid positions 19 and
20, which would yield a mature protein with a mass of
9,440 Da and a pI of 6.48. A comparison of the nucleotide
sequences encoding Sm13 and Sh13 shows 70% identity;
the full-length proteins are 55% identical and share a con-
served C-terminus as illustrated in Figure 1, which has a
predicted transmembrane domain [35,36] from residues
80 to 101 (in the full length sequence). The sequence is
consistent with a type 1 transmembrane protein and indi-
cates that only the final 3 residues at the C-terminus are
cytosolic.
Amino acid alignment of the S. haematobium Sh13 and the S. mansoni Sm13 (accession number AAC25419) proteins Figure 1
Amino acid alignment of the S. haematobium Sh13 and the S. mansoni Sm13 (accession number AAC25419) proteins.
Sh-13
Sm-13
1 56 
1 56 
MLI I CR I F VLCFI IEL IS S QSGP S P ----I N H G P KDVS IQTYPD EEIDPRPI V L E LKH E V
M I WK I L VLFMFVEL IS S EPEP E P EPVPVSRNSKDVS IQTDVD --L DPRFLLL D LKR E I
Sh-13
Sm-13
57 104 
57 104 
TKLKEALDSLVN KINA IPPSS IATKY IHNGLLSS IC ILLIVYYHLQKS
GRLKDTFNALVA KIDTIPPSS IATKY IHNGLLSS IC I IFT VYYHYKKS
Signal peptide
Transmembrane DomainBMC Infectious Diseases 2006, 6:96 http://www.biomedcentral.com/1471-2334/6/96
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Nucleotide accession number
The Sh13 cDNA sequence has been deposited in the Gen-
bank database at the National Centre for Biotechnology
Information under the bankit no 709821.
Characterisation of recombinant Sh13
The sequence encoding the mature Sh13 protein was
cloned into the pMal-c2x vector and the recombinant
Sh13-MBP fusion expressed in E. coli. Mass spectrometry
verified the predicted mass of the Sh13-MBP protein
(52,365 Da ± 12 Da), while digestion with Factor Xa gave
two products whose molecular weights were 42,490 Da ±
8, 20 Da and 9, 889 Da ±2, 25 Da (Figure 2), consistent
with those predicted for MBP and the mature Sh13 respec-
tively. Western blotting showed the protein to be recog-
nised by the human sera used in the study as well as by
sera from mice immunised with the MBP-Sh13 fusion
(data not shown).
Schistosome epidemiology in the study population
Parasitological examination gave an overall infection
prevalence of 62 % and a mean infection intensity of 39
eggs/10 ml of urine (SE = 9, with a range between 0 and
1000 eggs). Infection prevalence and intensity followed a
convex age-infection profile with infection levels rising to
peak in children 11 to 12 years old and infection intensity
declining faster than infection prevalence thereafter (Fig-
ure 3). The World Health Organisation denotes this prev-
alence level as high and infection intensity also as high as
defined by having more than 10% of the population with
more than 50 eggs/10 ml of urine (28 of the147 partici-
pants had more than 50 eggs per 10 ml urine) [37].
Coomassie Blue stained gel showing the Sh13-MBP fusionprotein in lane 1 and the two products; MBP and Sh13 of Factor Xa  digestion in lane 2 Figure 2
Coomassie Blue stained gel showing the Sh13-MBP fusionprotein in lane 1 and the two products; MBP and Sh13 of Factor Xa 
digestion in lane 2.
Mw KDa
MBP-SH13
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150
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25
20
15
200
MBP
Sh13
Lane 2 Lane 1BMC Infectious Diseases 2006, 6:96 http://www.biomedcentral.com/1471-2334/6/96
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Antibody responses
Initial titration assays showed that anti-Sh13 IgA, IgM and
IgE could not be detected (data not shown). The lack of an
anti-Sh13 IgM response also indicated that the recom-
binant antigen had not been contaminated by lipopolysa-
charides from the E. coli expression system. Subsequent
assays focused on IgG subclasses for both anti-Sh13 and
anti-SWAP responses. IgG3 was the predominant subclass
produced against Sh13 while low levels of IgG1 were
detectable in most people and showed little variation
across the population as shown in Figure 4a. Levels of
IgG2 and IgG4 were undetectable in most people and
when detected, were very low. The relative levels of IgG
subclasses produced against Sh13 differed from those
against SWAP to which IgG1 and IgG4 responses were the
predominant subclasses with little detectable IgG2 and
IgG3 as shown in Figure 4b. The relationship between the
predominant IgG subclasses and age also differed
between the two antigen preparations, with anti-SWAP
responses following the age-infection curve (Figure 4b).
Further immuno-epidemiological studies focused on the
anti-Sh13 IgG3, as this was the major subclass produced
against the recombinant antigen, and this isotype
increased markedly with age.
Immuno-epidemiological profile of anti-Sh13 antibody 
responses
Statistical analysis of the relationship between the levels
of anti-Sh13 and infection intensity, sex and age were con-
ducted. Prior to this, ANOVA procedures showed that
infection intensity varied significantly across the 2 year
age groups shown in Figure 3 (F = 2.689, df = 5, 147, p =
0.024). Subsequent post-hoc tests showed that infection
intensity in the younger age groups (7–8 years and 9–10
years, Figure 3) were similar, so these could be combined
to give one age group. Similarly, infection intensity did
not differ significantly between the 13–14 year olds and
the 15–16 year olds where infection intensity was declin-
ing, so these groups could also be combined into one
group. The oldest age group (17–18 year olds) had the
lowest infection intensity which differed significant from
that of 13–16 year olds, so they formed a separate age
group. The study population was therefore divided into
groups where infection was rising (pre- peak of infection
group) – participants 7 to 10 years old (n = 27), peaking
– participants 11 to 12 years old (n = 28), declining (post-
peak of infection group)-participants 13–16 years old (n
= 77) and lowest (lowest infection post-peak infection) –
participants 17–18 years old (n = 15).
Statistical analyses were subsequently conducted to deter-
mine if infection and antibody levels differed significantly
among the four groups into which the population was
partitioned and the results of these analyses are shown in
Table 1. The analyses indicated that infection intensity
and prevalence in the pre-peak of infection group were
significantly lower that those in the peak infection group
and this was matched by a significant increase in anti-
Sh13 IgG3 levels Comparisons between the age groups
where infection intensity peaked and declined showed a
reduction albeit non significant in infection intensity and
prevalence and antibody levels were largely unchanged
remaining high as shown in Figure 5. However, while lev-
els of infection continued to fall significantly as shown by
the comparison between the groups with declining infec-
tion and lowest infection, anti-Sh13 IgG3 levels contin-
ued to rise. Overall these analyses demonstrated that
infection levels and antibody levels rose together to peak
in the 11–12 year olds, but that the subsequent decline in
infection levels in 13–18 year olds was accompanied by a
continued rise antibody levels as shown in Figure 5.
Testing predictions from theoretical work
Theoretical work modelling the age profile of a protective
immune response in a helminth infection has predicted
that the relationship between the immune response and
infection intensity varies with host age [8,9]. Furthermore
the relationship between infection intensity and the
immune response will be strongest and show a positive
correlation in younger age groups. This correlation is pre-
dicted to subsequently decrease turning negative in older
age groups. Therefore the next step in out study was to
determine if the relationship between infection intensity
and anti-Sh13 levels differed between the different age
a) Infection levels of the study population divided into 2-year  age classes with sample sizes as follows 7–8 years old n = 12;  9–10 years old, n = 15; 11–12 years old, n = 28; 13–14 year  old, n = 46; 15–16 year old, n = 31; and 17–18 year old, n =  15 Figure 3
a) Infection levels of the study population divided into 2-year 
age classes with sample sizes as follows 7–8 years old n = 12; 
9–10 years old, n = 15; 11–12 years old, n = 28; 13–14 year 
old, n = 46; 15–16 year old, n = 31; and 17–18 year old, n = 
15. The histogram shows infection intensity (log10(x+1) 
transformed) with bars representing the standard error of 
the mean, while the line shows infection prevalence.
0
0.5
1
1.5
 7-8  9-10  11-12  13-14  15-16  17-18
age group (years)
i
n
f
e
c
t
i
o
n
 
i
n
t
e
n
s
i
t
y
 
0
25
50
75
100
i
n
f
e
c
t
i
o
n
 
p
r
e
v
a
l
e
n
c
eBMC Infectious Diseases 2006, 6:96 http://www.biomedcentral.com/1471-2334/6/96
Page 8 of 11
(page number not for citation purposes)
groups. Detailed statistical analyses allowing for sex and
age group showed that infection intensity did not have a
significant effect on anti-Sh13 IgG3 levels (F = 0.329, df =
1, 147, p = 0.567). When allowing for the effects of sex
and infection intensity, age group had a significant effect
on anti-Sh13 levels (F = 3.971, df = 3, 147, p = 0.009). The
predictions of the model were tested by analysing the
effect of the interaction between age and infection inten-
sity on anti-Sh13 IgG3 levels which was significant (F =
3.604, df = 3, 147, p = 0.015), so that the relationship
between anti-Sh13 IgG3 levels and infection intensity var-
ied depending on the age of the participant. This result
meant that it was necessary to determine how this rela-
tionship changed between the different age groups. This
was explored by correlation analysis in the different age
groups. The youngest age group (7–10 years old) showed
very little levels of anti-Sh13 IgG3 so were excluded from
the correlation analyses. The analyses showed that the
relationship varies between being positive and negative
with the strongest, and significant correlation between
infection intensity and anti-Sh13 IgG3 occurring in the
age group with the highest infection intensity, the correla-
tion subsequently reduces as shown in Figure 6. Tests for
homogeneity between the correlation coefficients showed
significant differences between the correlation coefficients
obtained for the peak infection group and declining (post-
peak of infection) (p < 0.01) and between the peak and
lowest infection group (p < 0.01). Taken together these
results are consistent with the predictions from the theo-
retical work.
Discussion
Identification and assessment of schistosome candidate
vaccine antigens has relied, and continues to rely, heavily
on studies of naturally acquired immune responses in
human populations [20,38,39]. However these studies
have been hampered by the lack of defined single anti-
gens, particularly for S. haematobium, and by methodolog-
ical difficulties in detecting responses associated with
resistance to infection/re-infection in field studies of
human populations [40,41]. In this study, Sh13, the puta-
tive orthologue of the S. mansoni tegumental protein
Sm13 was cloned from a cDNA library of adult schisto-
some worms [3]. There are no reported homologues from
other organisms and as yet, there have been no functional
studies of Sm13.
The recombinant Sh13 protein was recognised by mouse
sera following immunisation (data not shown) and was
reactive predominantly with IgG3 and also with IgG1
antibodies in sera from the Zimbabwean population
exposed to S. haematobium infection. The pattern of reac-
tivity of the sera against Sh13 differed from that against
adult worm crude antigens, where the predominant iso-
types were IgG1 and IgG4. Responses to crude antigens are
more heterogeneous as they are directed against multiple
epitopes present on numerous uncharacterised antigens
and therefore may mask the relationship between infec-
tion levels and responses to specific antigens [40].
The epidemiology of schistosome infection in this popu-
lation followed a convex shape of rising infection levels
(intensity and prevalence) peaking in childhood and
declining with age thereafter, a pattern which has been
attributed to cumulative exposure to infection and the
development of gradually acquired resistance to schisto-
somes [8,11,14,20,42]. The relationship between infec-
tion intensity and anti-Sh13IgG3 levels varied
significantly with age. The low levels of infection intensity
in the youngest age group were matched by low levels of
the antibody, presumably reflecting a low cumulative
exposure to adult parasite antigens in these young chil-
dren. This is consistent with an earlier report on children
resident in a S. haematobium endemic area in Zimbabwe
showing that the IgG3 response against adult worm anti-
gens developed slowly in young children 4 months- 6
years old [43]. Infection intensity and prevalence
increased significantly to peak in children 11–12 years
old. This significant change in infection levels was
matched by a significant increase in anti-Sh13IgG3. Cor-
relation analysis showed a significant positive association
between infection intensity and anti-Sh13IgG3 levels in
a) Age-antibody profile for anti-Sh13 IgG subclasses (square  root transformed) for the age groups in figure 3 showing that  IgG3 and IgG1 are the predominant subclasses produced  against this antigen Figure 4
a) Age-antibody profile for anti-Sh13 IgG subclasses (square 
root transformed) for the age groups in figure 3 showing that 
IgG3 and IgG1 are the predominant subclasses produced 
against this antigen. Diamonds represent IgG1, squares IgG2, 
triangles IgG3 and asterix IgG4. b) Age-antibody profile for 
anti-SWAP IgG subclasses (square root transformed) for the 
age groups in figure 3 showing that IgG1 and IgG4 are the 
predominant subclasses produced against this antigen.
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the age group presenting the highest egg counts allowing
for the conjecture that the anti-Sh13 IgG3 response is
stimulated by the increasing parasite burden. While infec-
tion intensity declined significantly in the oldest age
group, anti-Sh13 IgG3 levels remained high so that the
relationship between levels of this response and infection
intensity is uncoupled as illustrated by the changes in the
correlation between infection intensity and levels of the
antibody in this age group.
The changing relationship between anti-Sh13 IgG3 and
infection intensity with host age observed here was con-
firmed by the significant change in the correlation coeffi-
cient between the two variables with host age, and is
consistent with that predicted for immune responses asso-
ciated with resistance to infection [8]. Theoretical work
following the profile of a protective immune response
triggered by and directed against antigens in the adult
worms in a population, younger age groups as observed
here [8]. Furthermore, this correlation is predicted to fall
in age groups with declining infection levels, so that a sig-
nificant change in correlation coefficients with age is
expected to occur as observed here. Similar changes have
previously been reported in immuno-epidemiological
studies of Necator americanus IgG responses against adult
worm excretory/secretory antigens [44], and interpreted
as suggesting the development of protective parasite-spe-
cific acquired immunity [8,44].
There are several competing explanations for the falling
infection intensity/prevalence and uncoupling of S. hae-
matobium infection intensity and antibody levels observed
here. These include changes in exposure to infection
resulting in lower worm burdens and physiological
changes resulting in lower susceptibility to infection. In
this population data from the initial questionnaire studies
did not show a significant change in exposure to infective
water throughout the age range of the participants. In
addition, our previous studies and those of other groups
working on S. haematobium show that reduction in water
contact with increasing age is in itself insufficient explana-
tion for the observed decline in infection levels [14,45-
48]. Age-related physiological changes have also been sug-
gested as a possible explanation for the development of
innate resistance to infection, but evidence for this from
field studies is still lacking. The alternative explanation is
the development of schistosome-specific acquired immu-
nity, [14,20,42] and the patterns of infection and anti-
body responses in our study are consistent with the effects
of acquired immunity against the parasite.
If the expression pattern of Sh13 is similar to that of
Sm13, which is expressed only in adult worms [3], then
the anti-Sh13 response is being elicited by adult worms
(both living and dying) and is directed against adult
worms. In S. mansoni, the protein has been immunolocal-
ised to the tegument and therefore is accessible to the
Age-antibody profile for anti-Sh13 IgG3 (square root trans- formed) Figure 5
Age-antibody profile for anti-Sh13 IgG3 (square root trans-
formed). This figure gives more detail on the anti-Sh13 IgG3 
profile shown in Figure 4a, by showing the antibody levels 
relative to the partitioning of the population by infection 
intensity and also giving the standard error of the mean rep-
resented by bars on the graph.
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Table 1: Comparison of infection and antibody levels between the four groups.
Age Groups Infection intensity Infection prevalence Anti-Sh13 IgG3
Pre-peak vs. peak t = -1.942, df = 53 p = 0.029 χ2 = 4.114, df = 1, p = 0.043 t = -1820, df = 53, p = 0037
Pre-peak vs. declining t = -1.062, df = 102, p = 0.145 χ2 = 4.503, df = 1, p = 0.034 t = -1.441, df = 102, p = 0.077
Pre-peak vs. lowest t = 1.709, df = 40, p = 0.048 χ2 = 0.019, df = 1, p = 0.890 t = -2.906, df = 40, p = 0.003
Peak vs. declining t = 1.438, df = 103, p = 0.077 χ2 = 0.145, df = 1, p = 0.704 t = 0.679, df = 103, p = 0.25
Peak vs. lowest t = 3.170, df = 41, p = 0.002 χ2 = 2.563, df = 1, p = 0.109 t = -1.165, df = 41, p = 0.126
Declining vs. lowest t = 2.625, df = 90, p = 0.005 χ2 = 2.376, df = 1, p = 0.123 t = -2.044, df = 90, p = 0.022
The table compares infection intensity, prevalence and anti-Sh13 IgG3 amongst the four groups which the population has been partitioned as shown 
in Figure 3. Results from post-hoc tests are presented after one way ANOVA showed that infection intensity and anti-sh13 IgG3 levels differed 
significantly across the 4 age groups (F = 3.863, df = 3, 147, p = 0.011 and F = 2.946, df = 3, 147, p = 0.045 for infection intensity and anti-sh13 IgG3 
respectively). Significant differences are highlighted in bold font.BMC Infectious Diseases 2006, 6:96 http://www.biomedcentral.com/1471-2334/6/96
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host's immune system. Work to characterise the expres-
sion of Sh13 is now underway. From the present work, we
can conclude that the profile of anti-Sh13 IgG3 is consist-
ent with that of a protective response, but we have yet to
establish that the anti-Sh13 response contributes to,
rather than simply, reflects the development protective
immunity against schistosome infections. We have
obtained encouraging results from our preliminary vacci-
nation studies in 10 hamsters which have shown that
Sh13 stimulates an antibody response in hamsters and
that vaccinated hamsters have little or no infection com-
pared to unvaccinated controls which had heavy infection
and liver pathology (data not shown). These studies are
now being repeated using a larger sample size. Clearly,
protective immunity will be multifaceted involving differ-
ent cellular and humoral responses to several antigens.
Conclusion
We have identified and characterised a novel S. haemato-
bium antigen Sh13, a putative tegumental protein, and
shown that it is recognised predominantly by IgG3 anti-
bodies from people infected with/exposed to S. haemato-
bium parasites. We have also shown that, the anti-Sh13
IgG3 response is maximal in older individuals with the
lowest infection intensity, and that the age profile of the
relationship between anti-Sh13 IgG3 and infection inten-
sity is consistent with that predicted by theoretical work
for a protective response stimulated by and directed
against adult worms.
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